18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer

Journal of Nuclear Medicine

Volumn 53, Issue 9, 2012, Pages 1337-1344

  Song, Bong Il ^a   Lee, Sang Woo ^a   Jeong, Shin Young ^a   Chae, Yee Soo ^a   Lee, Won Kee ^b   Ahn, Byeong Cheol ^a   Lee, Jaetae ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

18F FDG PET CT; Breast cancer; Lymph nodes; Prognosis; SUV

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR; TRASTUZUMAB; DIAGNOSTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANIMAL EXPERIMENT; ARTICLE; ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; ESTROGEN BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; WHOLE BODY SCINTISCANNING; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84866184695     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098640     Document Type: Article

References (34)

1. American Cancer Society. Breast Cancer Facts & Figures 2011-2012. Atlanta, Georgia: American Cancer Society, Inc.
2. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer. 1983;52:1551-1557.
3. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
4. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89-112.
5. Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET. Cancer Imaging. 2008;8:70-80.
6. 18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
7. 18F-fluoro-2-deoxy-glucose- positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
8. Munker R, Glass J, Griffeth LK, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol. 2004;15:1699-1704.
9. 18F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma? Nuklearmedizin. 2011;50:116-121.
10. Song B-I, Hong C, Lee H, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117-124.
11. 18F]- fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. Eur J Nucl Med Mol Imaging. 2009;36:1783-1793.
12. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer. 2010;116:1469-1475.
13. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol. 2005;23:1664-1673.
14. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
15. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172.
16. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207-219.
17. Ferguson DJ, Meier P, Karrison T, Dawson PJ, Straus FH, Lowenstein FE. Staging of breast cancer and survival rates: an assessment based on 50 years of experience with radical mastectomy. JAMA. 1982;248:1337-1341.
18. Dent DM. Axillary lymphadenectomy for breast cancer: paradigm shifts and pragmatic surgeons. Arch Surg. 1996;131:1125-1127.
19. 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med. 2010;51:1191-1197.
20. 18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250-258.
21. 18F]-D-glucose. Cancer. 1998;82:2227-2234.
22. 18F]2-deoxy-2- fluoro-Dglucose positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273-278.
23. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46-52.
24. 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med. 2006;47:419-425.
25. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507.
26. Cook NR. Use and misuse of the receiver operating characteristics curve in risk prediction. Circulation. 2007;115:928-935.
27. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890.
28. Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer. 1997;76:1234-1240.
29. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125-138.
30. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.
31. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
32. 18F-FDG PET in malignant tumors. J Nucl Med. 2008;49:1804-1808.
33. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771-1777.
34. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683-687.